Abeona Therapeutics (ABEO) Profit After Tax (2011 - 2026)

Abeona Therapeutics' Profit After Tax history runs 16 years deep, the most recent figure standing at -$17.2 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 42.38% year-over-year to -$17.2 million in Q1 2026; TTM through Mar 2026 was $66.7 million, a 250.71% increase from a year earlier, with the FY2025 full-year figure at $67.1 million, up 205.25% from the prior year.
• Profit After Tax improved to -$17.2 million in Q1 2026 per ABEO's latest filing, from -$24.6 million in the prior quarter.
• Across five years, Profit After Tax topped out at $113.7 million in Q2 2025 and bottomed at -$31.6 million in Q1 2024.
• The 5-year median for Profit After Tax is -$11.8 million (2023), against an average of -$6.1 million.
• Across the five-year window, Profit After Tax sank 306.49% in 2023 and jumped 1434.8% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$7.2 million in 2022, then slumped by 130.24% to -$16.6 million in 2023, then soared by 43.99% to -$9.3 million in 2024, then plunged by 164.37% to -$24.6 million in 2025, then increased by 29.85% to -$17.2 million in 2026.
• Per Business Quant, the three latest ABEO Profit After Tax figures stand at -$17.2 million (Q1 2026), -$24.6 million (Q4 2025), and -$5.2 million (Q3 2025).